ArticleMedicine2025
APOA1BP and natural killer cells as diagnostic and pathophysiological biomarkers in schizophrenia-associated cognitive impairment: A multi-cohort bioinformatics analysis.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia (SZ) is frequently accompanied by cognitive impairment, yet validated molecular biomarkers remain limited. This study aimed to identify immune-related biomarkers, particularly APOA1BP and natural killer (NK) cells, through integrative bioinformatics analyses. Three gene expression omnibus transcriptomic datasets (GSE93987, GSE87610, GSE73129) were analyzed. Differentially expressed genes (DEGs) were identified and evaluated using Weighted Gene co-expression Network Analysis (WGCNA) and LASSO regression. Immune cell infiltration was assessed by single-sample gene set enrichment analysis (ssGSEA). Diagnostic performance of candidate genes was validated in independent cohorts using receiver operating characteristic analysis. Seventy DEGs were identified, mainly involved in extracellular matrix and cell adhesion. Four candidate genes (APOA1BP, C12orf57, MRPL46, ZDHHC11) were highlighted, with APOA1BP consistently downregulated in SZ. ROC analysis demonstrated diagnostic potential (AUC up to 0.76), though performance varied across tissues. NK cell infiltration was significantly elevated in SZ and negatively correlated with APOA1BP and MRPL46. Validation confirmed APOA1BP as the most robust biomarker in DLPFC-derived datasets, while olfactory epithelial-derived samples showed limited significance, likely reflecting tissue-specific heterogeneity. This multi-cohort bioinformatics analysis identifies APOA1BP and NK cells as promising biomarkers in SZ-associated cognitive impairment. While findings are correlative, they suggest that immune-metabolic interactions may contribute to SZ pathophysiology. Future research should validate these biomarkers in larger, clinically annotated cohorts and explore their mechanistic and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.